These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1494 related articles for article (PubMed ID: 29560639)

  • 1. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
    Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
    Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
    Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
    [No Abstract]   [Full Text] [Related]  

  • 4. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
    Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
    J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy.
    Osipov A; Nissen N; Rutgers J; Dhall D; Naziri J; Chopra S; Li Q; Hendifar AE; Tuli R
    Ann Surg Oncol; 2017 Nov; 24(12):3674-3682. PubMed ID: 28871564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of coeliac axis resection in resected ductal adenocarcinoma of the distal pancreas: A result of tumour topography or a prognostic factor?
    Liu B; Wu J; Li C; Li Y; Qiu H; Lv A; Liu Q; Liu D; Wang Z; Hao C
    Pancreatology; 2022 Jan; 22(1):112-122. PubMed ID: 34764022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
    Kim NH; Kim HJ
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Surgical therapy of pancreatic cancer - 5 years survival].
    Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
    Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
    Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
    Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.
    Serrano PE; Cleary SP; Dhani N; Kim PT; Greig PD; Leung K; Moulton CA; Gallinger S; Wei AC
    Ann Surg Oncol; 2015 Apr; 22(4):1160-7. PubMed ID: 25348784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection.
    Ilmer M; Schiergens TS; Renz BW; Schneider C; Sargut M; Waligora R; Weniger M; Hartwig W; Ceyhan GO; Friess H; Werner J; D'Haese JG
    Surg Oncol; 2019 Dec; 31():16-21. PubMed ID: 31473583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
    Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
    Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
    Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
    Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma.
    Ruess DA; Makowiec F; Chikhladze S; Sick O; Riediger H; Hopt UT; Wittel UA
    BMC Surg; 2015 Nov; 15():123. PubMed ID: 26615588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.
    Riediger H; Keck T; Wellner U; zur Hausen A; Adam U; Hopt UT; Makowiec F
    J Gastrointest Surg; 2009 Jul; 13(7):1337-44. PubMed ID: 19418101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
    Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
    J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.